<DOC>
	<DOC>NCT02742090</DOC>
	<brief_summary>This is a Phase 2, open-label, study of TGR-1202, a PI3K delta inhibitor, administered as a single agent in Chronic Lymphocytic Leukemia (CLL) patients who are intolerant to prior BTK inhibitors (ibrutinib, other) or prior PI3K delta inhibitors (idelalisib, other)</brief_summary>
	<brief_title>Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) Discontinuation on prior BTK inhibitor or PI3K delta inhibitor due to adverse events within prior 9 months Presence of measurable disease Progression on prior BTK or PI3K delta inhibitor Prior treatment with TGR1202 Richter's transformation or CLL transformation to aggressive lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CLL</keyword>
</DOC>